Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLG2071
- Development stage
- Phase 3
- Administration
- Intravenous
01
Overview
QLG2071 is an investigational drug being evaluated for the treatment of hypertensive emergency and sub-emergency. It is currently in Phase 3 clinical trials, where it is compared to clevidipine (Cleviprex), a well-established intravenous antihypertensive agent. The specific mechanism of action for QLG2071 has not been disclosed in public sources, but its use as a comparator to clevidipine suggests it may act as a calcium channel blocker or have similar rapid blood pressure-lowering effects suitable for acute settings[1][3][7][8]. The developer and manufacturer information are not explicitly stated in available sources.
Beyond the preview
Go deeper on QLG2071.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLG2071.